, Last Revised, 2009.

N. Burton, Living with Schizophrenia, p.20, 2012.

B. Kirkpatrick, W. S. Fenton, and W. T. Carpenter, The NIMH-MATRICS consensus statement on negative symptoms, Schizophr Bull, vol.32, issue.2, pp.214-219, 2006.

J. J. Blanchard, A. M. Kring, and W. P. Horan, Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia, Schizophr Bull, vol.37, issue.2, pp.291-299, 2011.

J. Makinen, J. Miettunen, and E. Jaaskelainen, Negative symptoms and their predictors in schizophrenia within the Northern Finland, Birth Cohort. Psychiatry Res, vol.178, issue.1, pp.121-125, 1966.

C. L. Hovington and M. Lepage, Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia, Expert Rev Neurother, vol.12, issue.1, pp.53-69, 2012.

M. Carbon and C. U. Correll, Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia, CNS Spectr, vol.19, issue.1, p.53, 2014.

A. Millier, M. Horváth, and F. Ma, Healthcare resource use in schizophrenia, EuroSC findings, J Market Access Health Policy, vol.5, p.1372027, 2017.

J. P. Selten, D. Wiersma, and R. J. Van-den-bosch, Discrepancy between subjective and objective ratings for negative symptoms, J Psychiatr Res, vol.34, issue.1, pp.11-13, 2000.

J. Makinen, J. Miettunen, and M. Isohanni, Negative symptoms in schizophrenia: a review, Nord J Psychiatry, vol.62, issue.5, pp.334-341, 2008.

R. Bottlender, T. Sato, and C. Groll, Negative symptoms in depressed and schizophrenic patients: how do they differ?, J Clin Psychiatry, vol.64, issue.8, pp.954-958, 2003.

R. J. Willke, Measuring the value of treatment to patients: patient-reported outcomes in drug development. Am Health Drug Benefits, vol.1, pp.34-40, 2008.

A. European-medicines, Committee for Medicinal Products for Human use (CHMP): "Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products, 2005.

U. , Patientreported outcome measures. use in medical product development to support labeling claims, 2009.

H. Schipper, J. J. Clinch, and C. Olweny, Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven Publishers, pp.11-23, 1996.

, Health related of quality of life research, International Society for Quality of Life Research (ISOQOL)

C. Acquadro, R. Berzon, and D. Dubois, Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, Value Health, vol.6, issue.5, pp.522-531, 2001.

A. Millier, E. Clay, and I. Charaf, Outcomes instruments in schizophrenia: a review of psychometric properties, Open J Med Psychol, vol.3, issue.2, pp.141-156, 2014.

L. Boyer, M. C. Simeoni, and A. Loundou, The development of the S-QoL 18: a shortened quality of life questionnaire for patients with schizophrenia, Schizophr Res, vol.121, issue.1-3, pp.241-250, 2010.

J. Carlson, S. Ochoa, and J. M. Haro, Adaptation and validation of the quality-of-life scale: satisfaction with Life Domains Scale by Baker and Intagliata, Compr Psychiatry, vol.50, issue.1, pp.76-80, 2009.

M. Franz, M. Fritz, and B. Gallhofer, QLiS-development of a schizophrenia-specific quality-of-life scale, Health Qual Life Outcomes, vol.10, p.61, 2012.

M. Franz, M. Fritz, and T. Meyer, Discriminant and convergent validity of a subjective quality-of-life instrument aimed at high content validity for schizophrenic persons, Qual Life Res, vol.22, issue.5, pp.1113-1122, 2013.

P. Auquier, M. C. Simeoni, and C. Sapin, Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL, Schizophr Res, vol.63, issue.1-2, pp.137-149, 2003.

F. Baker and J. Intagliata, Quality of life in the evaluation of community support systems, Eval Progr Plann, vol.5, pp.69-79, 1982.

A. G. Awad, L. N. Voruganti, and R. J. Heslegrave, A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation, International Journal Quality Life Aspects Treatment, Care Rehabilitation, vol.6, issue.1, pp.21-26, 1997.

K. Baumstarck, M. Boucekine, and L. Boyer, Quantification of relevance of quality of life assessment for patients with cognitive impairment: the suitability indices, BMC Neurol, vol.14, p.78, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01097448

K. Baumstarck, L. Boyer, and M. Boucekine, Self-reported quality of life measure is reliable and valid in adult patients suffering from schizophrenia with executive impairment, Schizophr Res, vol.147, issue.1, pp.58-67, 2013.

M. Savill, S. Orfanos, and U. Reininghaus, The relationship between experiential deficits of negative symptoms and subjective quality of life in schizophrenia, Schizophr Res, vol.176, issue.2-3, pp.387-391, 2016.

, Storf M The impact of FDA and EMA guidances regarding Patient Reported Outcomes (PRO) on the drug development and approval process. Scientific examination work to obtain the title "Master of Drug Regulatory Affairs, 2013.

J. M. Haro, C. Altamura, and R. Corral, Understanding the impact of persistent symptoms in schizophrenia: crosssectional findings from the Pattern study, Schizophr Res, vol.169, issue.1-3, pp.234-240, 2015.

, Harvard health publications, the negative symptoms of schizophrenia, 2006 update. The Family Health Guide, 2006.

D. I. Velligan, L. Alphs, and S. Lancaster, Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia, Psychiatry Res, vol.169, issue.2, pp.97-100, 2009.

B. J. Kinon, D. L. Noordsy, and H. Liu-seifert, Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning, J Clin Psychopharmacol, vol.26, issue.5, pp.453-461, 2006.

J. Rabinowitz, C. G. Berardo, and D. Bugarski-kirola, Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis, Schizophr Res, vol.150, issue.2-3, pp.339-342, 2013.

S. Z. Levine and S. Leucht, Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms, Schizophr Res, vol.145, issue.1-3, pp.125-127, 2013.

T. Wobrock, B. Guse, and J. Cordes, Left prefrontal highfrequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial, Biol Psychiatry, vol.77, issue.11, pp.979-988, 2015.

J. Cordes, P. Falkai, and B. Guse, Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham-controlled, randomized multicenter study, Eur Arch Psychiatry Clin Neurosci, vol.259, issue.2, pp.189-97, 2009.

J. H. Schoemaker, W. T. Jansen, and J. Schipper, The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial, J Clin Psychopharmacol, vol.34, issue.2, pp.190-198, 2014.

Y. Hirayasu, S. Sato, and H. Takahashi, A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, BMC Psychiatry, vol.16, p.66, 2016.

S. R. Kay, A. Fiszbein, and L. A. Opler, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, vol.13, issue.2, pp.261-276, 1987.

W. Guy, Rockville: US Department Health, Education, and Welfare publication, pp.218-222, 1976.

D. Addington, J. Addington, and E. Maticka-tyndale, Assessing depression in schizophrenia: the Calgary Depression Scale, Br Journal Psychiatry Suppl, vol.22, pp.39-44, 1993.

G. Chouinard, L. Annable, and B. D. Jones, The extrapyramidal symptom rating scale, Canadian Journal of Neurological Sciences, vol.22, pp.39-44, 1980.

M. Rothman, L. Burke, and P. Erickson, Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report. Value Health, vol.12, pp.1075-1083, 2009.

S. N. Haynes, D. Richard, and E. S. Kubany, Content validity in psychological assessment: A functional approach to concepts and methods, Psychol Assess, vol.7, issue.3, pp.238-247, 1995.

M. J. Miller, RES 600: Graduate Research Methods. Western International University, 2011.

M. Terre, K. D. Blanche, and . Ripamftss, , 2008.

P. W. Stratford, J. M. Binkley, and D. L. Riddle, Sensitivity to change of the Roland-Morris Back Pain Questionnaire: part 1, Phys Ther, vol.78, issue.11, pp.1186-1196, 1998.

M. Hersen, . Cshoaba, and . San-diego, , p.32, 2006.

L. Prieto, D. Novick, and J. A. Sacristan, Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study, Acta Psychiatrica Scandinavica Supplementum, issue.416, pp.24-29, 2003.

J. E. Ware, K. K. Snow, and M. Kolinski, SF-36 Health Survey Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Centre, 1993.

W. The and . Group, The World Health Organization Quality of Life Assessment (WHOQOL), Soc Sci Med, vol.46, issue.12, pp.1569-1585, 1998.

S. M. Skevington, M. Lotfy, O. Connell, and K. A. , The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Quality of life research: an international journal of quality of life aspects of treatment. Care and Rehabilitation, vol.13, pp.299-310, 2004.

C. Lancon, P. Auquier, and R. Launois,

, L'Encephale, vol.26, issue.4, pp.11-16, 2000.

J. Oliver, P. J. Huxley, and S. Priebe, Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile, Socio Psychiatry Psychiatr Epidemiol, vol.32, pp.76-83, 1997.

S. Priebe, P. Huxley, and S. Knight, Application and results of the Manchester Short Assessment of Quality of Life (MANSA), Int J Soc Psychiatry, vol.45, issue.1, pp.7-12, 1999.

D. Naber, S. Moritz, and M. Lambert, Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs, Schizophr Res, vol.50, issue.1-2, pp.79-88, 2001.

L. De-haan, M. Weisfelt, and P. M. Dingemans, Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale, Psychopharmacology, vol.162, issue.1, pp.24-28, 2002.

A. L. Montejo, J. C. Lauffer, and J. Cuervo, Validation of a specific measure to assess health-related quality of life in patients with schizophrenia and bipolar disorder: the 'Tolerability and quality of life

, Ann Gen Psychiatry, vol.10, p.6, 2011.

A. L. Montejo, J. Correaslauffer, and F. Porras, Spanish validation of tool questionnaire: a new instrument to assess quality of life in patients with schizophrenia and bipolar disorder, Eur Psychiatry, vol.24, issue.1, p.947, 2009.

P. Diaz, C. Mercier, and R. Hachey, An evaluation of psychometric properties of the client's questionnaire of the Wisconsin Quality of Life Index-Canadian version (CaW-QLI), Qual Life Res, vol.8, issue.6, pp.509-514, 1999.

L. Nadalet, F. S. Kohl, and D. Pringuey, Validation of a subjective quality of life questionnaire (S.QUA.LA) in schizophrenia, Schizophr Res, vol.76, issue.1, pp.73-81, 2005.

A. Pitkanen, M. Valimaki, and J. Endicott, Assessing quality of life in patients with schizophrenia in an acute psychiatric setting: reliability, validity and feasibility of the EQ-5D and the Q-LES-Q, Nord J Psychiatry, vol.66, issue.1, pp.19-25, 2012.

M. Ritsner, R. Kurs, and A. Gibel, Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients, Qual Life Res, vol.14, issue.7, pp.1693-1703, 2005.

G. Wilkinson, B. Hesdon, and D. Wild, Self-report quality of life measure for people with schizophrenia: the SQLS, Br J Psychiatry, vol.177, pp.42-46, 2000.

Y. Kaneda, A. Imakura, and A. Fujii, Schizophrenia Quality of Life Scale: validation of the Japanese version, Psychiatry Res, vol.113, issue.1-2, pp.107-113, 2002.